Table 1. Clinical features and treatment of sixty-nine patients (pts) enrolled in the BEVA2007 trial.
| Features | Patients who received palliative RT (45 patients) | Patients who did not receive palliative RT (24 patients) |
|---|---|---|
| Sex | ||
| Male | 37 (82.2%) | 16 (66.7%) |
| Female | 8 (17.8%) | 8 (33.3%) |
| RT sites | ||
| 1Bone | 19 (42.2%) | NA |
| 2Lung | 5 (11.1%) | NA |
| 3Nodes | 2 (4.4%) | NA |
| 4WBRT | 18 (40%) | NA |
| 5SRS brain | 3 (6.7%) | NA |
| Histology | ||
| Adenocarcinoma | 31 (68.9%) | 16 (66.7%) |
| Squamous | 7 (15.6%) | 2 (8.3%) |
| Large cell carcinoma | 1 (0.2%) | 4 (16.7%) |
| NAS | 6 (13.3%) | 2 (8.3%) |
Patients received four mCH courses according to the mPEBev regimen, and did not show progression of disease along the treatment. Forty-five of these patients received additional palliative radiotherapy (RT) on quality of life threatening lesions.
Radiotherapy Treatment and dosage: 1Thirty Gy in ten RT fractions (three patients received additional treatment with 20 Gy in five fractions); 2-3Fifty-four Gy in 30 RT fractions; 4Thirty Gy in ten RT fractions; 5Twenty Gy in one single fraction.